Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials

Documents similaires

• Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
  par: Weijun Gu, et autres
  Publié: (2025)
• Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
  par: Manish R. Bhise, et autres
  Publié: (2025)
• Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis
  par: Ludovico Di Gioia, et autres
  Publié: (2025)
• Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
  par: Emily R. Hankosky, et autres
  Publié: (2025)
• Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials
  par: Sahana Shetty, et autres
  Publié: (2024)